Alto Neuroscience Inc

ANRONYSE · USD
24.91USD-2.21 (-8.15%)
2510

Alto Neuroscience Inc (ANRO) Historical Volatility

ANRO's 30 day historical volatility is 82.30%, in the 69th percentile of readings over the past year. This is an average percentile, meaning Alto Neuroscience Inc shares have moved roughly in line with their typical range. ANRO's 30 day implied volatility sits at 90.30%, with an IV Rank of 19.44%, leaving IV 8.00 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.

Read more

Tracking ANRO historical volatility helps you see how much Alto Neuroscience Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ANRO's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ANRO 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ANRO's 30 day historical volatility, or ANRO HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ANRO's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD.

Historical Volatility

HV Percentile
69thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)82.30%

HV Percentile69th

Implied Volatility (30d)90.30%

IV Rank19.44%

IV Minus HV+8.00%

As of Nov 16, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 16, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →